Biovail Won't Let Generic Wellbutrin XL Get It Down
This article was originally published in The Pink Sheet Daily
GlaxoSmithKline partner Biovail is accelerating R&D in the face of a generic challenge to the antidepressant.
You may also be interested in...
A generic version of GlaxoSmithKline's antidepressant Wellbutrin XL (bupropion) could launch later this year after an Aug. 1 decision in a California district court
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.